An example of the clashes the FDA had with pressure groups, involved the drug company Upjohn and their patented drug Panalba. Panalba was a combination of tetracycline, an inexpensive and effective generic drug, with novobiocin, a more toxic antibacterial with a different spectrum of activity. Although Upjohn had been marketing the drug for 7 years, they had not done any of the required studies on the efficacy of it and so the FDA under Ley moved to decertify it. Ley met tremendous opposition from Upjohn.